Ionis Pharmaceuticals (IONS) PT Raised to $77 at Jefferies
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- US stock futures rise after previous session's selloff
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Supermicro probe finds no senior management link to export violations
- SpaceX shares fall as second lockup period ends
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
Ionis announces positive detailed results from the HALOS Study of ION582 in people with Angelman syndrome
July 22, 2024 7:00 AM EDTION582 showed robust and consistent benefit in communication, cognition and motor function in a broad patient population evaluated with a comprehensive set of assessment tools that collect input from parents and clinicians97% of patients in the medium and high dose groups saw improvement in overall Angelman syndrome symptoms as measured by the SAS-CGI-C Improvements on the Bayley-4 in cognition, communication and motor function exceeded those observed in natural history studiesIonis plans to initiate Phase 3 development in H1 2025Ionis to host webcast on Monday, July 22 at... More
Ionis to hold second quarter 2024 financial results webcast
July 19, 2024 8:24 AM EDTWebcast scheduled for Thursday, August 1 at 11:30 a.m. Eastern Time
CARLSBAD, Calif., July 19, 2024 /PRNewswire/... More
Ionis completes enrollment in pivotal trial evaluating zilganersen in people living with Alexander disease
July 18, 2024 7:00 AM EDTZilganersen is the first investigational medicine in clinical development for people with Alexander disease, a rare, life-threatening neurological condition
CARLSBAD, Calif., July 18, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS)Â announced today that it has completed enrollment in the pivotal trial of zilganersen... More
